Compare OHI & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OHI | ALGN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.7B |
| IPO Year | 2001 | 2000 |
| Metric | OHI | ALGN |
|---|---|---|
| Price | $50.11 | $175.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $46.55 | ★ $199.82 |
| AVG Volume (30 Days) | ★ 1.7M | 969.6K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | ★ 25.16 | 0.53 |
| EPS | 0.47 | ★ 1.57 |
| Revenue | ★ $1,190,099,000.00 | $387,126,000.00 |
| Revenue This Year | $4.70 | $5.78 |
| Revenue Next Year | $5.38 | $4.62 |
| P/E Ratio | ★ $105.83 | $113.42 |
| Revenue Growth | 13.19 | ★ 23.95 |
| 52 Week Low | $37.70 | $122.00 |
| 52 Week High | $50.10 | $208.31 |
| Indicator | OHI | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 48.70 |
| Support Level | $43.10 | $175.35 |
| Resistance Level | N/A | $186.44 |
| Average True Range (ATR) | 0.87 | 7.72 |
| MACD | 0.10 | -0.51 |
| Stochastic Oscillator | 81.13 | 37.65 |
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.